Several large meta-analyses examining heterogenous treatment effects in placebo-controlled CVOTs have been conducted for GLP1-RA76,83,84,90–97, with the majority of studies focusing on whether prior established CVD modifies the relative effect of GLP1-RA on MACE and/or heart failure. Here, GLP1R is linked to heart failure.